8-K: INVO Fertility Amends Preferred Stock Terms and Secures Dilutive Financing Amidst Financial Restructuring

INVO Fertility, Inc. has amended the terms of its Series C-2 Convertible Preferred Stock and entered into new agreements with an institutional investor, involving a debt-to-equity exchange and a cash investment, under highly dilutive conditions.

Summary

• INVO Fertility, Inc. filed a Certificate of Amendment to its Series C-2 Convertible Preferred Stock, authorizing 20,000 shares with a stated value of $1,000 per share and a par value of $0.0001.
• The Series C-2 Preferred Stock carries a 10% annual dividend rate, payable in cash or preferred shares, which becomes cumulative and accrues from the 91st day after the Initial Issuance Date (October 11, 2024).
• The initial conversion price for the Series C-2 Preferred Stock is $0.95 per share, subject to adjustments for dilutive issuances, stock splits, and other corporate events.
• A 'Triggering Event' (e.g., trading suspension, failure to deliver shares, default on $500,000+ indebtedness, bankruptcy, material adverse effect) will automatically increase the dividend rate to a punitive 20% per annum.
• In a liquidation event, holders of Series C-2 Preferred Stock are entitled to receive the greater of 125% of their Conversion Amount or the as-converted common stock value, ranking senior to common stock.
• The company amended its Securities Purchase Agreement to allow the Holder (FIVE NARROW LANE LP) to exercise an 'Additional Investment Right' of up to $10,000,000 in C-2 Preferred Shares, either for cash or by exchanging portions of the existing Debenture.
• Under an 'AIR Exercise and Reload Agreement', the Holder agreed to acquire 1,800 shares of C-2 Preferred Stock (aggregate stated value $1,800,000) in exchange for $1,800,000 in principal amount of the Debenture plus accrued interest.
• As consideration for this exchange, INVO Fertility also agreed to issue 630 shares of new unregistered C-2 Preferred Stock to the Holder.
• On June 26, 2025, the Holder exercised its Additional Investment Right to acquire 500 shares of C-2 Preferred Stock (aggregate stated value $500,000) for $500,000 in cash, which resulted in the conversion price adjusting to $0.95 per share.
• The company is prohibited from issuing common stock or equivalents for 30 trading days post-closing of the AIR Exercise and from engaging in 'Variable Rate Transactions' for one year, with certain exceptions.

Sentiment

Score: 3

Explanation: While the company secured financing and converted some debt, the terms are highly dilutive and indicative of financial distress or a very high-risk profile. The extensive investor protections and punitive default clauses suggest a precarious financial position for common shareholders.

Positives

• Secured additional financing through a combination of debt-to-equity exchange and a cash investment, providing capital to the company.
• The exchange of $1,800,000 in Debenture principal for preferred stock reduces the company's outstanding debt obligations.
• The company commits to seeking stockholder approval for the conversion of preferred shares and maintaining its Nasdaq listing, which are crucial for liquidity and compliance.

Negatives

• The terms of the Series C-2 Convertible Preferred Stock, particularly the price-based conversion adjustment (lowest of current or 85% of lowest VWAP), are highly dilutive to existing common shareholders.
• A high dividend rate of 10% per annum, escalating to 20% upon a 'Triggering Event', represents a significant cost of capital for the company.
• The extensive list of 'Triggering Events' and associated penalties (e.g., 1% daily penalty for conversion failure) indicates a company operating under strict financial covenants and potentially facing liquidity challenges.
• The 'Make-Whole Amount' provision, requiring payment of an additional year's dividends upon conversion or repayment, adds to the overall cost of this financing.
• The prohibition on 'Variable Rate Transactions' for one year, while intended to prevent certain dilutive financings, also limits the company's flexibility in raising future capital.

Risks

• Significant potential for dilution of common shareholders due to the conversion of Series C-2 Preferred Stock and New C-2 Preferred, especially with the price-based conversion price adjustment mechanism.
• High financial distress risk indicated by numerous 'Triggering Events' (e.g., failure to pay, default on indebtedness, bankruptcy, material adverse effect) and the punitive 20% default dividend rate.
• Market price volatility risk, as the conversion price is tied to the Volume Weighted Average Price (VWAP), meaning lower stock prices could lead to more shares being issued and increased dilution.
• Regulatory and listing risk if the company fails to obtain stockholder approval for common stock issuance upon conversion or fails to maintain its Nasdaq listing.
• Limited future financing flexibility due to the one-year prohibition on 'Variable Rate Transactions', which could be problematic if the company requires immediate capital.
• Ongoing debt obligations, including the Senior Secured Convertible Debenture, with a $500,000 default threshold, pose continued financial risk.
• Operational risk, as a 'Material Adverse Effect' on the company's business, assets, operations, or financial condition constitutes a 'Triggering Event'.

Future Outlook

The company plans to file a Current Report on Form 8-K to disclose the material terms of these transactions. It will also seek stockholder approval for the conversion of preferred shares into common stock and file a resale registration statement for the newly issued shares. The company is committed to maintaining its Nasdaq listing and will hold regular stockholder meetings until the necessary approvals are obtained.

Industry Context

This announcement reflects a common financing strategy for small-cap companies, particularly in sectors like fertility or biotech, that may face challenges in securing traditional, less dilutive funding. The complex structure involving convertible preferred stock, debentures, and stringent investor protections is typical when companies require capital but have limited options, often indicating a higher risk profile or a need to fund ongoing operations and growth initiatives.

Comparison to Industry Standards

• The 10% annual dividend rate on preferred stock, escalating to 20% upon default, is significantly higher than typical preferred stock yields for financially stable companies, suggesting a high-risk investment or a strong bargaining position by the investor.
• The conversion price adjustment mechanism, which allows the conversion price to be reset to 85% of the lowest VWAP, is a 'toxic' or 'death spiral' financing feature. This is generally considered highly unfavorable and dilutive for common shareholders compared to standard industry practices for healthy companies, often seen in distressed or early-stage ventures.
• The extensive list of 'Triggering Events' and the associated punitive measures (e.g., high default dividend rate, daily penalties for conversion failures) indicate a very protective investor and suggest the company may be operating under precarious financial conditions, which is not typical for well-capitalized industry peers.
• The 125% liquidation preference for preferred shareholders is a strong investor protection, ensuring a substantial return before common shareholders in a liquidation event, which is a common feature in high-risk preferred equity but can be more aggressive than in less risky investments.
• The prohibition on 'Variable Rate Transactions' for one year, while potentially protecting against future toxic financings, also limits the company's flexibility in raising capital, which could be a disadvantage compared to competitors with broader financing options.

Corporate Governance

Related Party Transactions

• The document details significant transactions with FIVE NARROW LANE LP, an institutional investor that is an existing holder of the company's Series C-2 Convertible Preferred Stock and a Senior Secured Convertible Debenture. These transactions include an amendment to the Securities Purchase Agreement, a debt-to-equity exchange, and a cash investment, all of which are material dealings with a specific, significant investor.

Stakeholder Impact

• **Shareholders (Common Stock)**: Face significant potential for dilution due to the highly dilutive conversion terms of the preferred stock, including price-based adjustments, which could substantially reduce their equity stake and per-share value.
• **Preferred Shareholders (FIVE NARROW LANE LP)**: Benefit from enhanced protections, a high dividend yield (10%, 20% default), and favorable conversion terms (including anti-dilution and make-whole provisions), ensuring a strong position and potential for significant returns. The debt-to-equity conversion also restructures their investment.
• **Creditors**: The exchange of a portion of the Debenture for preferred stock reduces the company's outstanding debt, which could be viewed positively by other creditors, but the continued existence of a senior secured debenture indicates ongoing debt obligations.
• **Employees/Management**: The capital infusion provides some operational runway, but the strict covenants, potential for further dilution, and the company's apparent need for such financing terms suggest ongoing financial challenges that could impact job security or future compensation.

Next Steps

• File a Current Report on Form 8-K with the SEC disclosing all material terms of the transactions.
• File a registration statement (Form S-3 or S-1) for the resale of the New Underlying Shares within 30 calendar days of obtaining stockholder approval.
• Use commercially reasonable efforts to cause the resale registration statement to become effective within 60-90 calendar days following stockholder approval.
• Hold an annual or special meeting of stockholders on or prior to 90 days following the closing date of the AIR Exercise to obtain stockholder approval for the issuance of common stock upon conversion of the Series C-2 Preferred.
• If stockholder approval is not obtained at the first meeting, call a meeting every 90 days thereafter to seek approval until it is secured or the New C-2 Preferred are no longer outstanding.
• Apply to list or quote all of the New Underlying Shares on the Nasdaq Capital Market and promptly secure their listing, and maintain the listing and trading of its Common Stock on a Trading Market.

Key Dates

Recommendation

Keywords

INVO Fertility, IVF, Series C-2 Convertible Preferred Stock, SEC filing, 8-K, preferred stock, convertible debt, capital raise, debt exchange, dilution, corporate governance, financial reporting, NASDAQ, NAYA Biosciences, FIVE NARROW LANE LP